222
Participants
Start Date
October 27, 2010
Primary Completion Date
January 15, 2014
Study Completion Date
February 9, 2018
ruxolitinib tablets
Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
Best Available Therapy (BAT)
Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
Birmingham
Scottsdale
Pomona
Sacramento
San Diego
Bridgeport
New Haven
Boynton Beach
Fort Myers
Jacksonville
Winter Park
Boise
Chicago
Lafayette
Scarborough
Baltimore
Columbia
Southfield
Jefferson City
St Louis
Omaha
Morristown
Somerville
Charleston
Greenville
Nashville
Houston
Seattle
Buenos Aires
Brisbane
Parkville
Tweed Heads
Antwerp
Bruges
Brussels
Leuven
Hamilton
Montreal
Toronto
Beijing
Hangzhou
Avignon
Bayonne
Brest
Lille
Nantes
Paris
Vandœuvre-lès-Nancy
Aachen
Berlin
Bonn
Freiburg im Breisgau
Hamburg
Jena
Magdeburg
Mannheim
Minden
München
Ulm
Budapest
Kecskemét
Szeged
Szombathely
Bari
Bergamo
Bologna
Florence
Milan
Napoli
Orbassano
Pavia
Reggio Calabria
Roma
Varese
Vicenza
Chiba
Chuo-city Yamanashi
Maebashi
Nagoya-city Aichi
Osaka
Tokyo
Enschede
Rotterdam
Moscow
Saint Petersburg
Seoul
A Coruña
Barcelona
Las Palmas de Gran Canaria
Madrid
Majadahonda
Málaga
Pamplona
Salamanca
Valencia
Bangkok
Ankara
Istanbul
Izmir
Bournemouth
Cardiff
London
Lead Sponsor
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Incyte Corporation
INDUSTRY